It has been recently proposed to focus on the enteroendocrine cell dysfunction and to use GLP-1 analogs for the management of protracted diarrhea and diabetes in patients with heterozygous RFX6 mutations (16, 18). This evidence concerns the gene RFX6 and diabetes mellitus.